Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06172374
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
Sponsor: ReCode Therapeutics
View on ClinicalTrials.gov
Summary
Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.
Official title: DNAI1 Primary Ciliary Dyskinesia: Genetic Testing, Patient Finding and Increasing Disease Awareness Program
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2023-08-31
Completion Date
2025-12
Last Updated
2025-05-11
Healthy Volunteers
No
Conditions
Interventions
GENETIC
Sano Genetics Testing Kit
Genetic testing spit collection tubes for DNA testing
Locations (1)
ReCode Therapeutics, Inc.
Menlo Park, California, United States